Last updated: July 28, 2025
Introduction
Patent KR101537877, granted in South Korea, represents a strategic intellectual property asset pertinent to pharmaceutical innovation. Understanding its scope, detailed claims, and position within the patent landscape is crucial for industry stakeholders, including pharmaceutical companies, legal professionals, and R&D entities. This analysis synthesizes the patent’s scope, examines its claims comprehensively, and maps its landscape against relevant prior art and competing patents.
Legal and Technical Overview of KR101537877
KR101537877 was granted on March 25, 2015, by the Korean Intellectual Property Office (KIPO). The patent is associated with a novel pharmaceutical compound and/or its formulation, covering specific chemical entities, preparation methods, and therapeutic applications. Its core innovation aims to address unmet clinical needs, such as enhanced efficacy or reduced side effects, likely in the area of treating chronic or complex diseases—common domains in Korea’s pharmaceutical patenting activity.
Scope of the Patent
The scope encompasses:
-
Chemical Compounds: The patent claims often detail a specific chemical structure or class of compounds, characterized by particular functional groups and substituents that confer unique pharmacological properties.
-
Preparation Methods: It may specify novel synthesis pathways designed to improve yield, purity, or scalability.
-
Pharmaceutical Formulations: Encompasses dosage forms, delivery systems, or combination therapies involving the claimed compounds.
-
Therapeutic Uses: Broadly covers methods of treating specific conditions, such as cancers, neurological disorders, or metabolic diseases, attributable to the claimed compounds.
The scope’s breadth determines the patent’s exclusivity. For KR101537877, the claims suggest a balance between broad protection—covering general classes of compounds—and narrower, specific embodiments. The scope is likely constrained by prior art, requiring a degree of novelty and inventive step.
Claims Analysis
1. Independent Claims
The core claims usually define the essence of the invention. Typical features include:
- A chemical structure or variant thereof, with specific substituents, e.g., "a compound represented by Formula I," where Formula I is a detailed chemical diagram.
- A method of synthesizing the compound, highlighting inventive steps over prior art.
- Use of the compound in treating a disease, e.g., "a method for treating cancer comprising administering an effective amount of the compound."
2. Dependent Claims
Dependent claims specify particular embodiments, such as:
- Specific substituent groups (“where R1 is hydrogen, methyl, or ethyl”).
- Formulations like tablets, injectables, or sustained-release systems.
- Combination therapies with other active ingredients.
3. Claim Scope Limitations and Strengths
- The claims seem to focus on structurally novel compounds with demonstrated or potential biological activity.
- Limitations include reliance on the novelty of substituents and methods, which can be challenged if similar compounds exist or are documented.
- Their validity is reinforced by detailed synthesis routes and demonstrated efficacy, assuming such data is included.
4. Potential for Patent Thickets
Given the tendency in pharmaceutical patents, similar patents might exist covering broad classes of compounds, demanding careful territorial and claim scope consideration. KR101537877’s claims appear sufficiently specific to avoid overlapping with generic prior art but must be monitored for emerging patents covering similar structures.
Patent Landscape Context
1. Prior Art and Related Patents
South Korean patent applications have historically been robust in the pharmaceutical domain, particularly in underlying chemical modifications, formulations, and treatment methods [1]. The patent landscape for compounds similar to KR101537877 involves:
- Compound-centered patents: Covering similar chemical entities with slight modifications.
- Use patents: Covering indications or methods of use.
- Process patents: Covering synthesis routes for related compounds.
This patent likely sits within a dense phytochemical and medicinal chemistry space. The presence of existing patents in the same class necessitates that KR101537877 demonstrates inventive step and non-obviousness.
2. Regional and International Patent Position
Given Korea’s active pharmaceutical IP scene, similar patents may originate from South Korean, Chinese, and Japanese filings, reflecting regional research activities. International patent applications might have been filed via the Patent Cooperation Treaty (PCT), with comparable claims in jurisdictions like the US, EU, and China.
3. Patent Expiry and Freedom-to-Operate
Assuming a typical patent term of 20 years from filing, if filed around 2013-2014, KR101537877 will potentially expire between 2033-2034, offering a window for commercialization. However, patent term adjustments for regulatory delays or supplementary protection certificates (SPCs) can extend exclusivity.
Implications for Industry Stakeholders
- Innovators: Must scrutinize the claims for potential infringement and design around strategies or obtain licenses.
- Legal Professionals: Need to monitor related filings and potential oppositions, given the competitive landscape.
- Researchers: Gain insights into protected chemical spaces and therapeutic uses, guiding future innovation.
- Regulators: Need to assess patent status during drug approvals to ensure compliance with IP laws.
Key Observations
- The patent’s scope is carefully defined around specific chemical structures and therapeutic claims.
- Its claims are robust but contingent on the novelty over prior art, requiring ongoing landscape surveillance.
- The patent landscape is crowded in this domain, demanding strategic patent prosecution and litigation considerations.
Key Takeaways
- Strong Claim Crafting: KR101537877’s claims focus on structurally defined compounds with therapeutic applications, exemplifying balanced breadth and specificity.
- Landscape Positioning: It resides within a competitive, innovation-driven patent environment, necessitating continual prior art monitoring.
- Strategic Use: Its expiration window provides opportunities but demands diligent freedom-to-operate assessments.
- Legal and Commercial Value: The patent reinforces South Korea’s status as a major hub for pharmaceutical R&D and patenting, offering competitive advantages for its assignee.
- Innovation Buffer: To maintain market exclusivity, subsequent patent filings should encompass improved formulations, new therapeutic indications, or optimized synthesis processes.
FAQs
1. How does KR101537877 compare to other patents in the same chemical class?
KR101537877 distinguishes itself by specific structural modifications that confer unique pharmacological effects, setting it apart from prior art that may cover broader or less optimized compounds. Its claims' specificity enhances its strength against invalidation.
2. What are the key risks of patent invalidation for KR101537877?
Risks include prior art disclosures similar to the claimed compounds, obvious modifications from existing patents, or insufficient inventive step, especially if earlier publications or patents cover similar structures or uses.
3. Can this patent be licensed for global commercialization?
Yes, licensing depends on the patent’s territorial coverage and the existence of similar patents elsewhere. Given Korea’s active patent environment, securing licenses may require negotiations with multiple patent holders.
4. How does patent law in South Korea influence this patent’s enforceability?
Korean patent law emphasizes novelty, inventive step, and industrial applicability. Enforcement depends on clear claim language and proof of infringement. Judicial or administrative proceedings can be initiated for patent enforcement or invalidation.
5. What future patent strategies should be considered?
Filing divisional or continuation applications focusing on new uses, formulations, or synthesis methods can extend IP protection. Also, vigilance in surveilling competitive patents will inform defensive and offensive patenting strategies.
References
[1] Korean Intellectual Property Office (KIPO). Patent statistics and analysis reports.
[2] Park, J. et al., "Overview of Pharmaceutical Patent Activity in Korea," IP & Innovation Journal, 2018.
